What is it? Why is it important?

After a Routine-Monitoring-Visit (RMV), the monitor follows-up on site progress in order to ensure outstanding RMV findings are properly addressed. The aim is to ensure the ongoing safety of study participant (e.g. study risk-benefit) and the quality of study data.

 

During RMV follow-up, the site is expected to resolve outstanding issues within a given timeline. This is especially the case regarding serious findings (e.g. safety and quality concerns).

 

In the event a RMV finding cannot be resolved during follow-up, the SP-INV performs a risk assessment in order to decide whether the study must:

  • Be put on hold until issue resolution
  • Be adapted. An adaptation in study conduct will require a protocol amendment with subsequent approval by Ethics Committee (EC) and if applicable RA (e.g. Swissmedic)

 

What do I need to do?

As a study monitor responsible for site follow-up:

  • Write a short follow-up letter or e-mail to the Site-INV and:
    • Clearly describe findings
    • Mark findings that must be reported back once resolved
    • Include timelines for finding resolution (e.g. CAPAs)
  • Transmit the follow-up letter/e-mail within  10 to 20 business days, or as soon as possible in the event of serious findings 
  • Remotely check and answer ingoing queries regarding outstanding issues
  • Inform the study SP-INV of findings that remain unresolved, or study site non-compliance

 

Follow-up organisational matters may include:

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R2) – see in particular guidelines

  • 4.5 Protocol compliance
  • 5.18 Monitoring activities
  • 6.10 Access to source data / documents

 

ISO 14155 Medical Device – see in particular section (access liable to costs)

  • 9.2.4 Monitoring
Abbreviations
  • CAPA – Corrective and Preventive Actions
  • CTU – Clinical Trials Unit
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • ISF – Investigator Site File
  • IMP/IMD – Investigational Medicinal Product/Medical Device
  • ISO – International Organisation for Standardisation
  • RMV – Routine Monitoring Visit
  • Site-INV – Site Investigator
  • SP-INV – Sponsor Investigator
  • TMF – Trial Master File
Conduct ↦ Monitoring ↦ Routine Monitoring Visit ↦ Follow-Up
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Basic Drug or Device
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Conduct ↦ Monitoring ↦ Routine Monitoring Visit ↦ Follow-Up

Please note: the Easy-GCS tool is currently under construction.